《大行報告》瑞銀下調國壽(02628.HK)目標價至13.6元 評級「買入」
瑞銀髮表報告指,中國人壽(02628.HK)業績大致符合預期,首九個月新業務價值下跌15%,估計單計第三季爲下跌約20%,主要由於產品組合轉變。至於第三季的純利下跌24%至57億元人民幣,主因投資表現影響及準備金變動。
該行下調國壽今年盈利預測17%,反映第三季業績表現,明年及2024年則調低9%至13%;目標價由14.6元降至13.6元,評級維持「買入」。
踏入第四季,雖然該行認爲行業在危疾產品的消費需求上仍將面臨挑戰,但國壽提前啓動「開門紅」活動,可能有助緩和部分增長挑戰。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.